Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 17/20 | 0.84 |
| ▸ | ESRRB | O95718 | 1/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.84 |
| ▸ | ESRRG | P62508 | 1/20 | 0.84 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705251 | 1.00 | ESRRA (0.84) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650140 | 0.92 | ESRRA (1.00) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2699107 | 0.92 | ESRRA (1.00) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL31188051 | 0.92 | ESRRA (1.00) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL650141 | 0.92 | ESRRA (1.00) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4435911 | 0.87 | ESRRA (0.84) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4435916 | 0.87 | ESRRA (0.84) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL8156842 | 0.83 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2380997 | 0.83 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL2380995 | 0.83 | ESRRA (0.85) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| EP-2450352-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | ESRRA 2/4885ESRRB 9/4885ESR1 5/4885 |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | ESRRA 2/4885ESRRB 9/4885ESR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.